DAX19.306 +0,8%ESt504.787 +0,7%MSCIW3.759 +0,1%Dow44.121 +0,6%Nas18.943 -0,2%Bitcoin94.939 +0,9%Euro1,0398 -0,7%Öl74,89 +0,7%Gold2.706 +1,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 MicroStrategy 722713 Tesla A1CX3T Rheinmetall 703000 Bayer BAY001 Siemens Energy ENER6Y Amazon 906866 Volkswagen (VW) vz. 766403 EVOTEC 566480 NEL ASA A0B733 Deutsche Telekom 555750 Coinbase A2QP7J Mercedes-Benz Group (ex Daimler) 710000 Palantir A2QA4J Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht deutlich fester ins Wochenende -- Bitcoin knapp vor 100.000 US-Dollar -- VW drohen Warnstreiks ab Anfang Dezember -- Chef der US-Börsenaufsicht tritt ab -- RWE, Secunet, NEL im Fokus
Top News
NEL ASA-Aktie mit leichter Erholung nach Verlustserie: Analysten warnen vor möglicher Kapitalerhöhung NEL ASA-Aktie mit leichter Erholung nach Verlustserie: Analysten warnen vor möglicher Kapitalerhöhung
Wirecard-Aktionär will Schadenersatz - Musterprozess beginnt Wirecard-Aktionär will Schadenersatz - Musterprozess beginnt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

VistaGen Therapeutics Aktie

NeuKaufenVerkaufen
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone

WKNA2AJU8

ISINUS92840H2022

SymbolVTGN

VistaGen Therapeutics Aktien News

DatumMeistgelesen
BusinesswireVistagen to Present at the Stifel 2024 Healthcare Conference
BusinesswireVistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
BusinesswireVistagen to Present at the 2024 Neuroscience Education Institute Congress
BusinesswireVistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
BusinesswireVistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
BusinesswireVistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
BusinesswireVistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
BusinesswireVistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
BusinesswireVistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
BusinesswireVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
BusinesswireVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
BusinesswireVistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
BusinesswireVistagen to Present at the Jefferies Global Healthcare Conference
BusinesswireVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
BusinesswireVistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
BusinesswireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
BusinesswireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
BusinesswireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
BusinesswireVistagen to Present at Stifel 2024 Virtual CNS Days
BusinesswireVistagen to Present at TD Cowen 44th Annual Health Care Conference
BusinesswireVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
BusinesswireVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
BusinesswireVistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
BusinesswireVistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
BusinesswireVistagen to Present at Stifel 2023 Healthcare Conference
BusinesswireVistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
BusinesswireVistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
BusinesswireVistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
BusinesswireVistagen Announces Pricing of $100 Million Underwritten Offering
BusinesswireVistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
BusinesswireVistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
BusinesswireVistagen Appoints Cindy Anderson as Chief Financial Officer
BusinesswireSubsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
PR NewswireAffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
BusinesswireVistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
BusinesswireVistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
BusinesswireVistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
BusinesswireVistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
BusinesswireVistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
BusinesswireVistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

VistaGen Therapeutics News

VistaGen Therapeutics News: auf dieser Seite finden Sie alle VistaGen Therapeutics News und Nachrichten zur VistaGen Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch VistaGen Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um VistaGen Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.